Monday, July 31, 2017

Blood Cancer Journal - Table of Contents alert Volume 7 July 2017

If you are unable to see the message below, click here to view.
Blood Cancer Journal

TABLE OF CONTENTS

Volume 7, July 2017

In this issue
Original Articles
Letters to the Editor
Sign up for e-alerts Sign up for e-alerts
Web feed

Original Articles

Top

Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia

H-A Hou, J-W Lu, T-Y Lin, C-H Tsai, W-C Chou, C-C Lin, Y-Y Kuo, C-Y Liu, M-H Tseng, Y-C Chiang, Y-L Peng, J-L Tang, Z Gong, L-I Lin and H-F Tien

Blood Cancer J 2017 7: e588; 10.1038/bcj.2017.67

Abstract | Full Text

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells

N Shenoy, T Bhagat, E Nieves, M Stenson, J Lawson, G S Choudhary, T Habermann, G Nowakowski, R Singh, X Wu, A Verma and T E Witzig

Blood Cancer J 2017 7: e587; 10.1038/bcj.2017.65

Abstract | Full Text

MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma

J Xiong, L Wang, X-C Fei, X-F Jiang, Z Zheng, Y Zhao, C-F Wang, B Li, S-J Chen, A Janin, R P Gale and W-L Zhao

Blood Cancer J 2017 7: e582; 10.1038/bcj.2017.61

Abstract | Full Text

Letters to the Editor

Top

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

L Besse, M Kraus, A Besse, J Bader, T Silzle, T Mehrling and C Driessen

Blood Cancer J 2017 7: e589; 10.1038/bcj.2017.69

Full Text

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Z Gong, L J Medeiros, J E Cortes, L Zheng, J D Khoury, W Wang, G Tang, S Loghavi, R Luthra, W Yang, H M Kantarjian and S Hu

Blood Cancer J 2017 7: e583; 10.1038/bcj.2017.62

Full Text

Malignant T cells activate endothelial cells via IL-17F

B Lauenborg, I V Litvinov, Y Zhou, A Willerslev-Olsen, C M Bonefeld, C Nastasi, S Fredholm, L M Lindahl, D Sasseville, C Geisler, M M Wasik, T Krejsgaard, L M R Gjerdrum, L Iversen, N Odum and A Woetmann

Blood Cancer J 2017 7: e586; 10.1038/bcj.2017.64

Full Text

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis

M M Patnaik, M M Timm, R Vallapureddy, T L Lasho, R P Ketterling, N Gangat, M Shi, A Tefferi, E Solary, K K Reichard and D Jevremovic

Blood Cancer J 2017 7: e584;; 10.1038/bcj.2017.66

Full Text

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia

K Vargova, M Pesta, P Obrtlikova, N Dusilkova, L Minarik, J Vargova, A Berkova, Z Zemanova, K Michalova, M Spacek, M Trneny and T Stopka

Blood Cancer J 2017 7: e585; 10.1038/bcj.2017.63

Full Text

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature
 

No comments: